ClinicalTrials.gg
Not yet recruitingNCT07836023Updated Sep 23, 2026

PFAS Clinical Trial

A Phase 2 interventional study of Cholestyramine and Centrum in Environmental Exposure, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate whether treatment with cholestyramine for either one, two, three, or four months (up to 120 days), meaningfully influences per- and polyfluoroalkyl substances (PFAS) removal from the body.

Read the detailed description

The objective of this study is to assess whether cholestyramine, a bile acid sequestrant approved for the treatment of high cholesterol, can reduce the body burden of per- and polyfluoroalkyl substances (PFAS). PFAS are persistent chemicals that can accumulate in the body and have been associated with adverse health effects.

The study will enroll 300 adults from Rome and Calhoun, Georgia. Participants will complete four study visits which will include providing blood, urine, and fecal samples, as well as answering questionnaires. As part of the study, participants will be prescribed cholestyramine therapy for either one, two, three, or four months (up to 120 days) using a stepped-wedge trial study design. The study duration is 4 months for each participant.

Biospecimens will be stored for future research use. Written informed consent will be obtained from all participants before any study procedures are performed.

02

Conditions studied

  • Environmental Exposure

Keywords

  • PFAS
  • Perfluoroalkyl Substances
  • Polyfluoroalkyl Substances
  • Cholestyramine
  • Bile Acid Sequestrant
  • Microbiome
03

In context

Lead sponsor

Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.

Of its 238 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Residence in Floyd or Gordon County, Georgia
  • Residence in the study area for at least 5 years
  • No plans to relocate from the study area within the next 6 months
  • Able to communicate in English
  • Not currently pregnant
  • Primarily drinks tap water

Exclusion criteria

Exclusion Criteria:

  • Taken antibiotics in the last three months
  • Currently taking a BAS or drugs with known , bowel or stomach resections, malabsorptive conditions, documented celiac or irritable bowel disease
  • Stage 4 or higher chronic kidney disease
  • Hospitalization with acute condition in the last three months
  • History of malignant carcinoma.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Cholestyramine therapy Group

    Participants will receive cholestyramine therapy for one, two, three, or four months (up to 120 days in total).The dose will be escalated from 4 g/day during Week 1 to 8 g/day during Week 2 and 12 g/day thereafter for their remaining weeks while on the intervention (between 2-14 weeks depending on the study arm). Participants will additionally be given a bottle of Centrum-brand multivitamins at the first visit, with the option to take these vitamins daily as indicated on the multivitamin packing, while they are participating in the study (up to 120 days).

    Drug: Cholestyramine · Drug: Centrum

Interventions

  • Participants will be randomized to be prescribed cholestyramine therapy for one, two, three, or four months (up to 120 days in total). Participants will be prescribed cholestyramine at a dose of 4 grams daily (one dose) for the first week, 8 grams daily (two doses) for the second week, and 12 grams daily (three doses) for their remaining weeks while on the intervention (between 2-14 weeks depending on the study arm).

    Also known as: Cholestyramine resin

  • A bottle of Centrum-brand multivitamins will be provided at the first visit, with the option to take these vitamins daily as indicated on the multivitamin packing, while they are participating in the study (up to 120 days). The multivitamins are recommended as cholestyramine can lead to low levels of vitamins after long-term use.

    Also known as: Multivitamin, Centrum Adult Multivitamin

06

What researchers measure

Primary outcomes

  1. Serum NASEM ΣPFAS concentration

    The summed serum PFAS concentration (in ng/mL) according to a definition recommended by the National Academies of Sciences, Engineering, and Medicine (NASEM) will be measured.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

Secondary outcomes

  1. Shannon diversity index

    The Shannon Diversity Index will be used to assess the diversity of microorganisms in the gut microbiome. The measure considers both the number of different types of microorganisms present and their relative abundance. Higher values indicate greater microbial diversity.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

  2. Species richness

    Species richness will be used to assess the number of different microbial species detected in the gut microbiome. Higher values indicate a greater variety of microbial species.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

  3. Functional pathway abundance

    Functional pathway abundance will be used to assess the relative abundance of microbial genes associated with specific biological functions or metabolic pathways in the gut microbiome.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

  4. Strain richness

    The number of distinct microbial strains detected in the gut microbiome. Higher values indicate a greater variety of microbial strains.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

  5. Taxa abundance

    Taxa abundance will be used to assess changes in the relative abundance of specific groups of microorganisms in the gut microbiome.

    Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120 post-intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jun 2030, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 23, 2026
StartEst.
Nov 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07836023
Lead sponsor
Emory University
Responsible party
Stephanie Eick (Assistant Professor, Emory University) — Principal investigator
First posted
Sep 23, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 23, 2026

Study contacts

Stephanie Eick, PhD
Contact
ngapfas@emory.edu
404-829-4813
Alina Merceron, MPH
Contact
alina.merceron@emory.edu
Stephanie Eick, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cholestyramine Resin · Geritol

Start the discussion